iBio estimated 500 Million Dose Capacity for COVID-19 Vaccine from its FastPharming Facility

, , , , ,

On Apr. 27, 2020, iBio announced it has joined the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), one of 14 institutes in the Manufacturing USA Network. NIIMBL is a public-private partnership that aims to accelerate biopharmaceutical manufacturing innovations and establish an international, leading workforce to fundamentally strengthen the U.S. biopharmaceutical industry.

Tags:


Source: iBio
Credit: